Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMUM7HZ)

• Drug Name: Fluorouracil Drug Info
• Synonyms: 5-Fluorouracil; 51-21-8; fluorouracil; 5-FU; Fluoroplex; Adrucil; Efudex; Carac; Fluracil; Fluoroblastin; 5-fluoropyrimidine-2,4(1H,3H)-dione; Kecimeton; Timazin; Carzonal; Efudix; Arumel; Fluril; Queroplex; Fluracilum; Ulup; 5-Fluoracil; Phthoruracil; Fluro Uracil; 5-Fluoro-2,4(1H,3H)-pyrimidinedione; Ftoruracil; Fluorouracilum; Efurix; Fluri; 5 Fluorouracil; Effluderm (free base); 5-fluoro-1H-pyrimidine-2,4-dione; Fluorouracilo; Fluroblastin; Phtoruracil; 2,4-Dihydroxy-5-fluoropyrimidine; 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-; Adrucil; Effluderm; Fluorouracile; Fluoruracil; Fluracedyl; Flurodex; Neofluor; Onkofluor; Ribofluor; Tetratogen; URF; Allergan Brand of Fluorouracil; Biosyn Brand of Fluorouracil; CSP Brand of Fluorouracil; Cinco FU; Dakota Brand of Fluorouracil; Dermatech Brand of Fluorouracil; Dermik Brandof Fluorouracil; Ferrer Brand of Fluorouracil; Fluoro Uracile ICN; Fluorouracil GRY; Fluorouracil Mononitrate; Fluorouracil Monopotassium Salt; Fluorouracil Monosodium Salt; Fluorouracil Potassium Salt; Fluorouracil Teva Brand; Fluorouracile Dakota; Fluorouracile [DCIT]; Fluorouracilo Ferrer Far; Gry Brand of Fluorouracil; Haemato Brand of Fluorouracil; Haemato fu; Hexal Brand of Fluorouracil; ICN Brand of Fluorouracil; Inhibits thymilidate synthetase; Medac Brand of Fluorouracil; Neocorp Brand of Fluorouracil; Onkoworks Brand of Fluorouracil; Ribosepharm Brand of Fluorouracil; Riemser Brand of Fluorouracil; Roche Brand of Fluorouracil; Teva Brand of Fluorouracil; F 6627; F0151; IN1335; U 8953; Adrucil (TN); Carac (TN); Dakota, Fluorouracile; Efudex (TN); Fluoro-Uracile ICN; Fluoro-uracile; Fluoro-uracilo; Fluoroplex (TN); Fluorouracil-GRY; Fluorouracilo [INN-Spanish]; Fluorouracilum [INN-Latin]; Haemato-fu; Ro 2-9757; U-8953; Ro-2-9757; Fluorouracil (JP15/USP/INN); Fluorouracil [USAN:INN:BAN:JAN]; 1-fluoro-1h-pyrimidine-2,4-dione; 2,4-Dioxo-5-fluoropryimidine; 2,4-Dioxo-5-fluoropyrimidine; 5 FU Lederle; 5 FU medac; 5 Fluorouracil biosyn; 5 HU Hexal; 5-FU (TN); 5-FU Lederle; 5-FU medac; 5-Faracil; 5-Fluor-2,4(1H,3H)-pyrimidindion; 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]; 5-Fluor-2,4-dihydroxypyrimidin; 5-Fluor-2,4-dihydroxypyrimidin [Czech]; 5-Fluor-2,4-pyrimidindiol; 5-Fluor-2,4-pyrimidindiol [Czech]; 5-Fluoracil [German]; 5-Fluoracyl; 5-Fluoro-2,4-pyrimidinedione; 5-Fluoropyrimidin-2,4-diol; 5-Fluoropyrimidine-2,4-dione; 5-Fluorouracil-biosyn; 5-Fluoruracil; 5-Fluoruracil [German]; 5-Ftouracyl; 5-HU Hexal; 5-fluoro uracil; 5FU
• Therapeutic Class: Immunosuppressive Agents
• Cross-matching ID:
  PubChem CID: 3385
  ChEBI ID: CHEMBL185
  CAS Number: CAS 51-21-8
  TTD Drug ID: D05LEO
  VARIDT Drug ID: DR00153
  INTEDE Drug ID: DR0020
  ACDINA Drug ID: D01095

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
p53 signaling pathway	2.09	0.00e+0	63/73 (86.3%)	FAS;CDKN1A;DDB2;...
Small cell lung cancer	2.06	0.00e+0	90/92 (97.83%)	CDKN1A;DDB2;E2F2;...
Graft-versus-host disease	2.04	0.00e+0	32/42 (76.19%)	FAS;HLA-DQA1;GZMB;...
Intestinal immune network for IgA production	1.94	7.97e-3	38/48 (79.17%)	HLA-DQA1;TNFSF13;TGFB1;...
Fanconi anemia pathway	1.91	6.37e-3	36/54 (66.67%)	HES1;FANCL;USP1;...
Th1 and Th2 cell differentiation	1.91	5.31e-3	80/92 (86.96%)	HLA-DQA1;STAT1;MAF;...
Allograft rejection	1.86	9.10e-3	32/38 (84.21%)	FAS;HLA-DQA1;GZMB;...
Epstein-Barr virus infection	1.84	9.29e-3	189/202 (93.56%)	FAS;CDKN1A;DDB2;...
Herpes simplex virus 1 infection	1.82	1.30e-2	165/498 (33.13%)	FAS;HLA-DQA1;IKBKE;...
Cytosolic DNA-sensing pathway	1.79	1.59e-2	52/63 (82.54%)	IKBKE;CCL5;CXCL10;...
Influenza A	1.78	1.54e-2	156/172 (90.7%)	FAS;CXCL8;HLA-DQA1;...
IL-17 signaling pathway	1.76	1.95e-2	84/94 (89.36%)	CXCL8;FOSL1;IKBKE;...
Type I diabetes mellitus	1.76	1.80e-2	38/43 (88.37%)	FAS;HLA-DQA1;GZMB;...
Th17 cell differentiation	1.74	1.97e-2	95/107 (88.79%)	HLA-DQA1;STAT1;IL27RA;...
ECM-receptor interaction	1.73	2.27e-2	80/88 (90.91%)	THBS2;COL4A6;COL4A5;...
Viral protein interaction with cytokine and cytokine re...	1.72	2.26e-2	84/100 (84%)	CXCL8;CCL5;CXCL10;...
Base excision repair	1.70	2.81e-2	29/33 (87.88%)	PCNA;POLE3;POLD4;...
Hepatitis C	1.68	3.30e-2	139/157 (88.54%)	FAS;CDKN1A;E2F2;...
Autoimmune thyroid disease	1.68	3.24e-2	46/53 (86.79%)	FAS;HLA-DQA1;TG;...
Pancreatic cancer	1.67	3.19e-2	75/76 (98.68%)	CDKN1A;DDB2;E2F2;...
Mismatch repair	1.63	4.40e-2	22/23 (95.65%)	PCNA;MLH1;POLD4;...
Oocyte meiosis	-1.66	4.48e-2	90/129 (69.77%)	CDC23;IGF1R;PPP3R1;...
Steroid biosynthesis	-1.67	4.88e-2	19/20 (95%)	MSMO1;LBR;EBP;...
Terpenoid backbone biosynthesis	-1.69	4.43e-2	18/22 (81.82%)	PMVK;MVD;IDI1;...
Progesterone-mediated oocyte maturation	-1.70	4.50e-2	75/100 (75%)	CDC23;IGF1R;BRAF;...
Glycerolipid metabolism	-1.70	4.83e-2	44/61 (72.13%)	PLPP1;GLA;AGPAT4;...
AMPK signaling pathway	-1.76	2.99e-2	106/120 (88.33%)	TSC1;PRKAG2;CCNA2;...
Glycine, serine and threonine metabolism	-1.83	1.51e-2	31/40 (77.5%)	ALDH7A1;ALAS1;PSPH;...
Protein processing in endoplasmic reticulum	-1.89	7.07e-3	127/171 (74.27%)	SEC24D;EDEM3;SSR2;...
PPAR signaling pathway	-2.01	0.00e+0	66/74 (89.19%)	PLIN1;CYP7A1;APOC3;...
Ether lipid metabolism	-2.17	0.00e+0	32/49 (65.31%)	GAL3ST1;PLPP2;PLA2G10;...
Mineral absorption	-2.18	0.00e+0	48/60 (80%)	SLC30A1;SLC31A1;SLC34A2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	0.12uM - 10uM	6H, 24H, 48H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.002uM - 20uM	6H, 24H, 48H	Hide ▲

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	3H, 24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 20uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	25uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.002uM - 10uM	6H, 24H, 48H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	0.002uM - 10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.002uM - 20uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼